Molecular mechanisms of L-DOPA-induced dyskinesia

Nature Reviews Neuroscience

Volumn 9, Issue 9, 2008, Pages 665-677

  Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMINE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID; NEUROTRANSMITTER;

BASAL GANGLION; CLINICAL FEATURE; DYSKINESIA; HUMAN; MOLECULAR MECHANICS; MOTOR CORTEX; MUSCLE DENERVATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STRIATE CORTEX; SUBSTANTIA NIGRA; SYNAPTIC MEMBRANE;

ANIMALS; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; MODELS, NEUROLOGICAL; PARKINSON DISEASE;

EID: 50049087567     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn2471     Document Type: Review

References (201)

1. Tanner, C. M. & Ben-Shlomo, Y. Epidemiology of Parkinson's disease. Adv. Neurol. 80, 153-159 (1999).
2. Van Den Eeden, S. K. et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 157, 1015-1022 (2003).
3. Dorsey, E. R. et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68, 384-386 (2007).
4. Fahn, S. & Jankovic, J. Principles and Practice of Movement Disorders (Churchill Livingstone, Philadelphia, 2007). This excellent and comprehensive treatise on the basic science behind, and clinical manifestations of, movement disorders contains background information that puts this Review into a clinical perspective.
5. Jankovic, J. An update on the treatment of Parkinson's disease. Mt. Sinai J. Med. 73, 682-689 (2006).
6. Jankovic, J. & Stacy, M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 21, 677-692 (2007).
7. Ahlskog, J. E. & Muenter, M. D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16, 448-458 (2001).
8. Jankovic, J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. 20 (Suppl. 11), S11-S16 (2005).
9. Schrag, A., Ben-Shlomo, Y. & Quinn, N. How common are complications of Parkinson's disease? J. Neurol. 249, 419-423 (2002). This survey of the type and frequency of the motor complications that occur during the treatment of PD dealt with the incidence of dyskinesia and placed it in the overall picture of the chronic treatment of PD.
10. Holloway, R. G. et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol. 61, 1044-1053 (2004).
11. Oertel, W. H. et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov. Disord. 21, 343-353 (2006).
12. Rascol, O. et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342, 1484-1491 (2000).
13. DeLong, M. R. & Wichmann, T. Circuits and circuit disorders of the basal ganglia. Arch. Neurol. 64, 20-24 (2007).
14. Obeso, J. A. et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 23, S8-S19 (2000). This review of the organization of the basal ganglia and the alterations that occur in PD set the scene for the classical view of how these changes underlie motor symptoms and the onset of dyskinesia.
15. Wichmann, T. & DeLong, M. R. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv. Neurol. 91, 9-18 (2003).
16. Crossman, A. R. Neural mechanisms in disorders of movement. Comp. Biochem. Physiol. A 93, 141-149 (1989).
17. Crossman, A. R. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov. Disord. 5, 100-108 (1990).
18. Crossman, A. R. Functional anatomy of movement disorders. J. Anat. 196 (Pt 4), 519-525 (2000).
19. Gerfen, C. R. et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432 (1990).
20. Herrero, M. T. et al. Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum. Neurology 47, 219-224 (1996).
21. Vila, M. et al. Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: a cytochrome oxidase histochemistry study. Neuroscience 71, 903-912 (1996).
22. Vila, M. et al. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA. J. Neurosci. 17, 765-773 (1997).
23. Obeso, J. A. et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 62, S17-S30 (2004).
24. Sato, F., Lavallee, P., Levesque, M. & Parent, A. Single-axon tracing study of neurons of the external segment of the globus pallidus in primate. J. Comp. Neurol. 417, 17-31 (2000).
25. Parkin, S. G. et al. Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: a case series of 115 patients. Mov. Disord. 17, 682-692 (2002).
26. Heimer, G. et al. Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6- tetra-hydropyridine primate model of Parkinsonism. J. Neurosci. 26, 8101-8114 (2006). This paper subscribed to the emerging view that changes in the firing patterns of specific neurons in individual basal ganglia nuclei might be more important than overall changes in pathway activity.
27. Kuhn, A. A., Kupsch, A., Schneider, G. H. & Brown, P. Reduction in subthalamic 8-35 Hz oscillatory activity correlates with clinical improvement in Parkinson's disease. Eur. J. Neurosci. 23, 1956-1960 (2006).
28. Leblois, A. et al. Late emergence of synchronized oscillatory activity in the pallidum during progressive Parkinsonism. Eur. J. Neurosci. 26, 1701-1713 (2007).
29. Leblois, A., Boraud, T., Meissner, W., Bergman, H. & Hansel, D. Competition between feedback loops underlies normal and pathological dynamics in the basal ganglia. J. Neurosci. 26, 3567-3583 (2006). This paper posed a challenge to the classical view that the output from the basal ganglia is made up of the direct and indirect pathways. It suggested that alternative views now need to be considered when looking at the way in which the basal ganglia function in PD.
30. Boyce, S., Rupniak, N. M., Steventon, M. J. & Iversen, S. D. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin. Neuropharmacol. 13, 448-458 (1990).
31. Rajput, A. H., Fenton, M., Birdi, S. & Macaulay, R. Is levodopa toxic to human substantia nigra? Mov. Disord. 12, 634-638 (1997).
32. Ballard, P. A., Tetrud, J. W. & Langston, J. W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35, 949-956 (1985).
33. Bedard, P. J., Di, P. T., Falardeau, P. & Boucher, R. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res. 379, 294-299 (1986).
34. Clarke, C. E., Sambrook, M. A., Mitchell, I. J. & Crossman, A. R. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J. Neurol. Sci. 78, 273-280 (1987).
35. Pearce, R. K., Jackson, M., Smith, L., Jenner, P. & Marsden, C. D. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov. Disord. 10, 731-740 (1995). This paper provided an example of the MPTP-treated primate model of Parkinson's disease and of the induction of dyskinesia by L-DOPA treatment.
36. Quinn, N., Critchley, P. & Marsden, C. D. Young onset Parkinson's disease. Mov. Disord. 2, 73-91 (1987).
37. Gibb, W. R. & Lees, A. J. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 38, 1402-1406 (1988).
38. Di Monte, D. A. et al. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov. Disord. 15, 459-466 (2000).
39. Guigoni, C. et al. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur. J. Neurosci. 22, 283-287 (2005).
40. Schneider, J. S. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol. Biochem. Behav. 34, 193-196 (1989).
41. Schneider, J. S., Gonczi, H. & Decamp, E. Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms. Brain Res. 990, 38-44 (2003).
42. Linazasoro, G. New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol. Sci. 26, 391-397 (2005).
43. Togasaki, D. M. et al. Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. Neuropharmacology 48, 398-405 (2005).
44. Togasaki, D. M. et al. Levodopa induces dyskinesias in normal squirrel monkeys. Ann. Neurol. 50, 254-257 (2001).
45. Pearce, R. K., Heikkila, M., Linden, I. B. & Jenner, P. L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology (Berl.) 156, 402-409 (2001).
46. Olanow, C. W. et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov. Disord. 19, 997-1005 (2004).
47. Cedarbaum, J. M. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin. Pharmacokinet. 13, 141-178 (1987).
48. Gancher, S. T., Nutt, J. G. & Woodward, W. R. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients. Neurology 37, 940-944 (1987).
49. Kempster, P. A. et al. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 52, 718-723 (1989).
50. Nutt, J. G. Pharmacodynamics of levodopa in Parkinson's disease. Clin. Exp. Pharmacol. Physiol. 22, 837-840 (1995).
51. Rainero, I. et al. Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients. Ital. J. Neurol. Sci. 9, 255-259 (1988).
52. Goto, Y., Otani, S. & Grace, A. A. The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 53, 583-587 (2007).
53. Grace, A. A. The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug Alcohol Depend. 37, 111-129 (1995). This paper described the way in which the tonic and phasic effects of dopamine underlie the regulation of dopaminergic systems in the brain.
54. Obeso, J. A., Olanow, C. W. & Nutt, J. G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23, S2-S7 (2000).
55. Olanow, C. W., Obeso, J. A. & Stocchi, F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nature Clin. Pract. Neurol. 2, 382-392 (2006).
56. Olanow, C. W., Obeso, J. A. & Stocchi, F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 5, 677-687 (2006).
57. Nutt, J. G. Continuous dopaminergic stimulation: is it the answer to the motor complications of Levodopa? Mov. Disord. 22, 1-9 (2007).
58. Rascol, O. et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov. Disord. 21, 1844-1850 (2006).
59. Bibbiani, F., Costantini, L. C., Patel, R. & Chase, T. N. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp. Neurol. 192, 73-78 (2005).
60. Blanchet, P. J. et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J. Pharmacol. Exp. Ther. 272, 854-859 (1995). This study provided an example of how different delivery of the same drug by pulsatile or continuous administration results in differing degrees of dyskinesia in MPTP-treated primates.
61. Smith, L. A. et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov. Disord. 20, 306-314 (2005).
62. Stocchi, F., Vacca, L., Ruggieri, S. & Olanow, C. W. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch. Neurol. 62, 905-910 (2005).
63. Constantinescu, R., Romer, M., McDermott, M. P., Kamp, C. & Kieburtz, K. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov. Disord. 22, 1317-1319 (2007).
64. Hauser, R. A. et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov. Disord. 22, 2409-2417 (2007). This study investigated the long-term outcome of starting patients with PD on pulsatile L-DOPA therapy versus a longer-acting dopamine agonist.
65. Hadj, T. A., Gregoire, L., Bangassoro, E. & Bedard, P. J. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin. Neuropharmacol. 23, 195-202 (2000).
66. Jackson, M. J., Smith, L. A., Al-Barghouthy, G., Rose, S. & Jenner, P. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Exp. Neurol. 204, 162-170 (2007).
67. Smith, L. A. et al. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin. Neuropharmacol. 29, 112-125 (2006).
68. Blanchet, P. J., Konitsiotis, S. & Chase, T. N. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. 13, 798-802 (1998).
69. Blanchet, P. J., Metman, L. V. & Chase, T. N. Renaissance of amantadine in the treatment of Parkinson's disease. Adv. Neurol. 91, 251-257 (2003).
70. Chase, T. N., Oh, J. D. & Konitsiotis, S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J. Neurol. 247 (Suppl. 2), II36-II42 (2000). This paper focused attention on the importance of glutamatergic transmission and blockade of glutamate receptors in the control of dyskinesia induced by L-DOPA in MPTP-treated primates and patients with PD.
71. Del, D. P. et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov. Disord. 16, 515-520 (2001).
72. Verhagen, M. L. et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50, 1323-1326 (1998).
73. Gubellini, P. et al. Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission. Eur. J. Neurosci. 24, 1802-1814 (2006).
74. Benabid, A. L., Chabardes, S. & Seigneuret, E. Deep-brain stimulation in Parkinson's disease: long-term efficacy and safety - What happened this year? Curr. Opin. Neurol. 18, 623-630 (2005).
75. Benabid, A. L. et al. Surgical therapy for Parkinson's disease. J. Neural Transm. Suppl. 383-392 (2006).
76. Hurley, M. J. & Jenner, P. What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacol. Ther. 111, 715-728 (2006). This review of the reported changes in dopamine receptor expression illustrates the variability of reports on PD.
77. Aubert, I. et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 57, 17-26 (2005).
78. Guigoni, C. et al. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism. Relat. Disord. 11 (Suppl. 1), S25-S29 (2005).
79. 1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol. Dis. 26, 452-463 (2007).
80. Lee, J., Gomez-Ramirez, J., Johnston, T. H., Visanji, N. & Brotchie, J. M. Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease. Synapse 62, 310-313 (2008).
81. Bezard, E. et al. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol. Dis. 18, 323-335 (2005). This is an excellent example of several recent papers on the changes in striatal intracellular signalling cascades that occur after loss of nigrostriatal input and/or L-DOPA treatment.
82. 1 receptor functional hypersensitivity in Parkinson disease. J. Neurosci. 24, 7007-7014 (2004).
83. Blanchet, P., Bedard, P. J., Britton, D. R. & Kebabian, J. W. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys. J. Pharmacol. Exp. Ther. 267, 275-279 (1993).
84. Bordet, R. et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. USA 94, 3363-3367 (1997).
85. Bezard, E. et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nature Med. 9, 762-767 (2003).
86. Bordet, R., Ridray, S., Schwartz, J. C. & Sokoloff, P. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur. J. Neurosci. 12, 2117-2123 (2000).
87. Hurley, M. J., Stubbs, C. M., Jenner, P. & Marsden, C. D. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci. Lett. 214, 75-78 (1996).
88. Hurley, M. J., Jolkkonen, J., Stubbs, C. M., Jenner, P. & Marsden, C. D. Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res. 709, 259-264 (1996).
89. Tel, B. C. et al. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience 115, 1047-1058 (2002).
90. Zeng, B. Y., Pearce, R. K., MacKenzie, G. M. & Jenner, P. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur. J. Neurosci. 12, 1096-1104 (2000).
91. Henry, B., Duty, S., Fox, S. H., Crossman, A. R. & Brotchie, J. M. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp. Neurol. 183, 458-468 (2003).
92. Herrero, M. T. et al. Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease. Adv. Neurol. 69, 209-216 (1996).
93. Vila, M. et al. Consequences of nigrostriatal denervation on the gamma-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes. Neurology 46, 802-809 (1996).
94. Andersson, M., Hilbertson, A. & Cenci, M. A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6, 461-474 (1999).
95. Cenci, M. A. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids 23, 105-109 (2002).
96. Pavon, N., Martin, A. B., Mendialdua, A. & Moratalla, R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry 59, 64-74 (2006).
97. Valastro, B., Andersson, M., Lindgren, H. S. & Cenci, M. A. Expression pattern of JunD after acute or chronic L-DOPA treatment: comparison with ΔFosB. Neuroscience 144, 198-207 (2007).
98. Westin, J. E., Andersson, M., Lundblad, M. & Cenci, M. A. Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur. J. Neurosci. 14, 1171-1176 (2001). This study is an example of the pioneering work with the 6-OHDA-lesioned rat AIMs model of dyskinesia that is being undertaken to understand the gene changes that underlie the expression of involuntary movements.
99. Xu, Y., Sun, S. & Cao, X. Effect of levodopa chronic administration on behavioral changes and fos expression in basal ganglia in rat model of PD. J. Huazhong Univ. Sci. Technol. Med. Sci. 23, 258-262 (2003).
100. Calon, F. et al. Molecular basis of levodopa-induced dyskinesias. Ann. Neurol. 47, S70-S78 (2000).
101. A receptors in the striatopallidal complex. Brain Res. 680, 43-52 (1995).
102. A/ benzodiazepine receptor complex and GABA content. Neurochem. Int. 35, 81-91 (1999).
103. B receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments. Exp. Neurol. 163, 191-199 (2000).
104. Calon, F. & Di, P. T. Levodopa response motor complications - GABA receptors and preproenkephalin expression in human brain. Parkinsonism Relat. Disord. 8, 449-454 (2002).
105. Calon, F. et al. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov. Disord. 18, 241-253 (2003).
106. A receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys. Synapse 62, 101-109 (2008).
107. A and μ-opioid receptor binding in the globus pallidus and endopeduncular nucleus of animals symptomatic for and recovered from experimental Parkinsonism. Brain Res. 947, 284-289 (2002).
108. Aubert, I. et al. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol. Psychiatry 61, 836-844 (2007).
109. Brooks, D. J. PET studies and motor complications in Parkinson's disease. Trends Neurosci. 23, S101-S108 (2000).
110. Chen, L., Togasaki, D. M., Langston, J. W., Di Monte, D. A. & Quik, M. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys. Neuroscience 132, 409-420 (2005).
111. Piccini, P., Weeks, R. A. & Brooks, D. J. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann. Neurol. 42, 720-726 (1997).
112. Cohen, R. M., Carson, R. E., Aigner, T. G. & Doudet, D. J. Opiate receptor avidity is reduced in non-motor impaired MPTP-lesioned rhesus monkeys. Brain Res. 806, 292-296 (1998).
113. Cohen, R. M., Carson, R. E., Wyatt, R. J. & Doudet, D. J. Opiate receptor avidity is reduced bilaterally in rhesus monkeys unilaterally lesioned with MPTP. Synapse 33, 282-288 (1999).
114. Hallett, P. J. & Brotchie, J. M. Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. Mov. Disord. 22, 28-40 (2007).
115. Porrino, L. J., Viola, J. J., Crane, A. M. & Pontieri, F. E. Alterations in opiate receptor binding in MPTP-induced hemiparkinsonian monkeys. Neurosci. Lett. 127, 155-159 (1991).
116. Calon, F. et al. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127, 1075-1084 (2004).
117. Kase, H. et al. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 61, S97-S100 (2003).
118. Morelli, M. et al. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog. Neurobiol. 83, 293-309 (2007).
119. Cao, X. et al. Blockade of cannabinoid CB1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in MPTP-treated rhesus monkeys. J. Pharmacol. Exp. Ther. 323, 318-326 (2007).
120. Fox, S. H., Henry, B., Hill, M., Crossman, A. & Brotchie, J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 17, 1180-1187 (2002).
121. Fox, S. H., Lang, A. E. & Brotchie, J. M. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov. Disord. 21, 1578-1594 (2006).
122. Gomez-Ramirez, J., Johnston, T. H., Visanji, N. P., Fox, S. H. & Brotchie, J. M. Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 21, 839-846 (2006).
123. 2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 18, 872-883 (2003).
124. Calabresi, P., Giacomini, P., Centonze, D. & Bernardi, G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann. Neurol. 47, S60-S68 (2000).
125. Picconi, B. et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nature Neurosci. 6, 501-506 (2003). This paper contained important work on the alteration of information storage in the corticostriatal glutamatergic pathway after repeated L-DOPA treatment of 6-OHDA-lesioned rats and the induction of AIMs.
126. Picconi, B. et al. Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. Neurotoxicology 26, 779-783 (2005).
127. Calabresi, P., Picconi, B., Tozzi, A. & Di, F. M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 30, 211-219 (2007). This is an excellent review of the fundamental part that dopamine plays in regulating the plasticity of corticostriatal input to the striatum and of how loss of dopamine can lead to dysregulation in PD.
128. Picconi, B. et al. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol. Dis. 29, 327-335 (2008).
129. Surmeier, D. J., Ding, J., Day, M., Wang, Z. & Shen, W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 30, 228-235 (2007). This is an excellent review of the control of medium spiny neurons in the striatum by corticostriatal glutamatergic input and through dopaminergic regulation.
130. Blanchet, P. J. et al. Differing effects of N-methyl- D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 290, 1034-1040 (1999).
131. Hadj, T. A. et al. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol. Dis. 15, 171-176 (2004).
132. Morissette, M. et al. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Synapse 60, 239-250 (2006).
133. Morissette, M. et al. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov. Disord. 21, 9-17 (2006).
134. Nash, J. E. et al. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 165, 136-142 (2000).
135. Nash, J. E. et al. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 188, 471-479 (2004).
136. Papa, S. M. & Chase, T. N. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann. Neurol. 39, 574-578 (1996).
137. Verhagen, M. L., Del, D. P., Natte, R., van den Munckhof, P. & Chase, T. N. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 51, 203-206 (1998).
138. Bibbiani, F. et al. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp. Neurol. 196, 422-429 (2005).
139. Konitsiotis, S., Blanchet, P. J., Verhagen, L., Lamers, E. & Chase, T. N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54, 1589-1595 (2000).
140. Calon, F., Rajput, A. H., Hornykiewicz, O., Bedard, P. J. & Di, P. T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis. 14, 404-416 (2003).
141. Chase, T. N. Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism Relat. Disord. 10, 305-313 (2004).
142. Dunah, A. W. et al. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D- aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol. Pharmacol. 57, 342-352 (2000).
143. Hurley, M. J., Jackson, M. J., Smith, L. A., Rose, S. & Jenner, P. Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets. Eur. J. Neurosci. 21, 3240-3250 (2005).
144. Oh, J. D., Russell, D. S., Vaughan, C. L. & Chase, T. N. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res. 813, 150-159 (1998).
145. Oh, J. D., Vaughan, C. L. & Chase, T. N. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res. 821, 433-442 (1999).
146. Oh, J. D. & Chase, T. N. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids 23, 133-139 (2002). This paper underlined the concept that alterations in the phosphorylation of glutamate receptors are a key event in the disruption of striatal function that occurs in PD and in the genesis of dyskinesia.
147. Chase, T. N. & Oh, J. D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23, S86-S91 (2000).
148. Chase, T. N. & Oh, J. D. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann. Neurol. 47, S122-S129 (2000).
149. Chase, T. N., Bibbiani, F. & Oh, J. D. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox. Res. 5, 139-146 (2003).
150. Hallett, P. J. et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 48, 503-516 (2005).
151. Oh, J. D., Chartisathian, K., Ahmed, S. M. & Chase, T. N. Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats. J. Neurosci. Res. 72, 768-780 (2003).
152. Nicholas, A. P. et al. Striatal histone modifications in models of levodopa-induced dyskinesia. J. Neurochem. 106, 486-494 (2008). This recent paper suggested that the disruption of chromatin structure that is essential for the maintenance of neuronal plasticity might occur in dyskinesia.
153. Calabresi, P. et al. A critical role of the nitric oxide/ cGMP pathway in corticostriatal long-term depression. J. Neurosci. 19, 2489-2499 (1999).
154. 1/5 receptor-dependent mechanism. Neuropsychopharmacology 31, 493-505 (2006).
155. Bassilana, F. et al. Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease. Neurobiol. Dis. 20, 93-103 (2005).
156. Grunblatt, E. et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural Transm. 111, 1543-1573 (2004).
157. Konradi, C. et al. Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol. Dis. 17, 219-236 (2004).
158. Mandel, S. et al. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann. NY Acad. Sci. 1053, 356-375 (2005).
159. Kultima, K. et al. Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE. BMC Bioinformatics 7, 475 (2006).
160. Valastro, B. et al. Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia. J. Neurochem. 102, 1395-1409 (2007).
161. Ingham, C. A., Hood, S. H., van Maldegem, B., Weenink, A. & Arbuthnott, G. W. Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Exp. Brain Res. 93, 17-27 (1993).
162. Ingham, C. A., Hood, S. H., Taggart, P. & Arbuthnott, G. W. Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway. J. Neurosci. 18, 4732-4743 (1998).
163. McNeill, T. H., Brown, S. A., Rafols, J. A. & Shoulson, I. Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease. Brain Res. 455, 148-152 (1988).
164. Stephens, B. et al. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 132, 741-754 (2005). This study provided evidence that there is loss of spines on medium spiny neurons in PD.
165. Deutch, A. Y. Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson's disease. J. Neural Transm. Suppl. 67-70 (2006). This key paper showed that the loss of spines on striatal medium spiny neurons following dopaminergic denervation only occurs on the indirect output pathway.
166. Day, M. et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nature. Neurosci. 9, 251-259 (2006). This study is one of several that provided evidence that changes in the post-synaptic scaffolds that support glutamate receptors might occur in dyskinesia. Thus, glutamatergic transmission might also be altered at this level as well as following spine loss on medium spiny neurons.
167. Gardoni, F. et al. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J. Neurosci. 26, 2914-2922 (2006).
168. Misu, Y. & Goshima, Y. Is L-dopa an endogenous neurotransmitter? Trends Pharmacol. Sci. 14, 119-123 (1993).
169. Hamani, C., Neimat, J. & Lozano, A. M. Deep brain stimulation for the treatment of Parkinson's disease. J. Neural Transm. Suppl. 393-399 (2006).
170. Vitek, J. L. et al. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann. Neurol. 53, 558-569 (2003).
171. Manson, A. J. et al. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 124, 331-340 (2001).
172. O'Sullivan, J. D. & Lees, A. J. Use of apomorphine in Parkinson's disease. Hosp. Med. 60, 816-820 (1999).
173. Stocchi, F., Vacca, L., Ruggieri, S. & Olanow, C. W. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch. Neurol. 62, 905-910 (2005).
174. Schapira, A. H. & Obeso, J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann. Neurol. 59, 559-562 (2006).
175. Siderowf, A. & Stern, M. Clinical trials with rasagiline: evidence for short-term and long-term effects. Neurology 66, S80-S88 (2006).
176. Iravani, M. M. et al. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets. Eur. J. Neurosci. 13, 597-608 (2001).
177. Costa, S., Iravani, M. M., Pearce, R. K. & Jenner, P. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. Eur. J. Pharmacol. 412, 45-50 (2001).
178. Lindgren, H. S., Rylander, D., Ohlin, K. E., Lundblad, M. & Cenci, M. A. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav. Brain Res. 177, 150-159 (2007).
179. Cenci, M. A., Whishaw, I. Q. & Schallert, T. Animal models of neurological deficits: how relevant is the rat? Nature Rev. Neurosci. 3, 574-579 (2002). This Review describes evidence that the 6-OHDA-lesioned rat AIMs model of dyskinesia is a good model for studying the effects of drugs that are known to suppress dyskinesia in PD.
180. Dekundy, A., Lundblad, M., Danysz, W. & Cenci, M. A. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 179, 76-89 (2007).
181. Lundblad, M. et al. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15, 120-132 (2002).
182. Carta, M., Carlsson, T., Kirik, D. & Bjorklund, A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130, 1819-1833 (2007).
183. Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M. & Goetz, C. G. Levodopa-induced dyskinesias. Mov. Disord. 22, 1379-1389 (2007).
184. Fox, S. H., Lang, A. E. & Brotchie, J. M. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov. Disord. 21, 1578-1594 (2006).
185. Brotchie, J. M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov. Disord. 20, 919-931 (2005).
186. Jenner, P. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 61, S4-S11 (2003). This paper illustrated how changes in intracellular signalling pathways, such as the ERK1 and ERK2 pathway, have been consistently detected in the AIMs model and might provide an accessible means of investigating the basis of dyskinesia.
187. Westin, J. E., Vercammen, L., Strome, E. M., Konradi, C. & Cenci, M. A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 62, 800-810 (2007).
188. Li, W. et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr. Biol. 15, 1961-1967 (2005). This recent paper illustrated the potential for interfering with specific signalling pathways to be used as a means of finding new therapeutic approaches to the treatment of dyskinesia in PD.
189. Schuster, S. et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J. Neurosci. 28, 4311-4316 (2008).
190. Pirker, W. et al. Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions. Exp. Neurol. 169, 122-134 (2001).
191. Morissette, M. et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Brain Res. Mol. Brain Res. 49, 55-62 (1997).
192. Baldessarini, R. J. & Tarsy, D. Pathophysiologic basis of tardive dyskinesia. Adv. Biochem. Psychopharmacol. 24, 451-455 (1980).
193. Hong, J. S., Yoshikawa, K., Kanamatsu, T. & Sabol, S. L. Modulation of striatal enkephalinergic neurons by antipsychotic drugs. Fed. Proc. 44, 2535-2539 (1985).
194. Gunne, L. M. & Haggstrom, J. E. Experimental tardive dyskinesia. J. Clin. Psychiatry 46, 48-50 (1985).
195. Gunne, L. M., Haggstrom, J. E. & Sjoquist, B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 309, 347-349 (1984).
196. Harrison, P. J. The neuropathological effects of antipsychotic drugs. Schizophr. Res. 40, 87-99 (1999).
197. Meshul, C. K. & Casey, D. E. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res. 489, 338-346 (1989).
198. Meshul, C. K., Janowsky, A., Casey, D. E., Stallbaumer, R. K. & Taylor, B. Coadministration of haloperidol and SCH-23390 prevents the increase in "perforated" synapses due to either drug alone. Neuropsychopharmacology 7, 285-293 (1992).
199. Meshul, C. K., Janowsky, A., Casey, D. E., Stallbaumer, R. K. & Taylor, B. Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens, and medial prefrontal cortex. Psychopharmacology (Berl.) 106, 45-52 (1992). This paper illustrated the types of morphological changes that have been associated with chronic neuroleptic treatment in rats and the origins of tardive dyskinesia.
200. Meshul, C. K., Andreassen, O. A., Allen, C. & Jorgensen, H. A. Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol. Psychopharmacology (Berl.) 125, 238-247 (1996).
201. Herrero, M. T. et al. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP treated monkey striatum. Neuroscience 68, 1189-1198 (1995).